1
|
Noh E, Hong J, Yoo J, Jung J. Inference and forecasting phase shift regime of COVID-19 sub-lineages with a Markov-switching model. Microbiol Spectr 2023; 11:e0166923. [PMID: 37811981 PMCID: PMC10714866 DOI: 10.1128/spectrum.01669-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2023] [Accepted: 08/23/2023] [Indexed: 10/10/2023] Open
Abstract
IMPORTANCE Using regime-switching models, we attempted to determine whether there is a link between changes in severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) variants and infection waves, as well as forecasting new SARS-Cov-2 variants. We believe that our study makes a significant contribution to the field because it proposes a new approach for forecasting the ongoing pandemic, and the spread of other infectious diseases, using a statistical model which incorporates unpredictable factors such as human behavior, political factors, and cultural beliefs.
Collapse
Affiliation(s)
- Eul Noh
- Freddie Mac, Tysons Corner, Virginia, USA
| | - Jinwook Hong
- Artificial Intelligence and Big-Data Convergence Center, Gil Medical Center, Gachon University College of Medicine, Incheon, South Korea
| | - Joonkyung Yoo
- Department of Economics, Rutgers University--New Brunswick, New Brunswick, New Jersey, USA
| | - Jaehun Jung
- Artificial Intelligence and Big-Data Convergence Center, Gil Medical Center, Gachon University College of Medicine, Incheon, South Korea
- Department of Preventive Medicine, Gachon University College of Medicine, Incheon, South Korea
| |
Collapse
|
2
|
Lee HY, Jung YH, Jeung KW, Noh E, Lee J, Kim JC, Lee BK, Heo T, Min YI. Supranormal arterial oxygen tension only during the first six hours after cardiac arrest is associated with unfavourable outcomes. Acta Anaesthesiol Scand 2022; 66:1247-1256. [DOI: 10.1111/aas.14135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2022] [Revised: 07/21/2022] [Accepted: 08/08/2022] [Indexed: 11/26/2022]
Affiliation(s)
- Hyoung Youn Lee
- Trauma centre Chonnam National University Hospital Gwangju Republic of Korea
| | - Yong Hun Jung
- Department of Emergency Medicine Chonnam National University Hospital Gwangju Republic of Korea
- Department of Emergency Medicine Chonnam National University Medical School Gwangju Republic of Korea
| | - Kyung Woon Jeung
- Department of Emergency Medicine Chonnam National University Hospital Gwangju Republic of Korea
- Department of Emergency Medicine Chonnam National University Medical School Gwangju Republic of Korea
| | - Eul Noh
- Department of Emergency Medicine Chonnam National University Hwasun Hospital Hwasun‐gun Jeollanam‐do Republic of Korea
| | - Jiho Lee
- Department of Emergency Medicine Chonnam National University Hospital Gwangju Republic of Korea
| | - Jung Chul Kim
- Division of Trauma Surgery, Department of Surgery Chonnam National University Hospital Gwangju Republic of Korea
| | - Byung Kook Lee
- Department of Emergency Medicine Chonnam National University Hospital Gwangju Republic of Korea
- Department of Emergency Medicine Chonnam National University Medical School Gwangju Republic of Korea
| | - Tag Heo
- Department of Emergency Medicine Chonnam National University Hospital Gwangju Republic of Korea
- Department of Emergency Medicine Chonnam National University Medical School Gwangju Republic of Korea
| | - Yong Il Min
- Department of Emergency Medicine Chonnam National University Hospital Gwangju Republic of Korea
- Department of Emergency Medicine Chonnam National University Medical School Gwangju Republic of Korea
| |
Collapse
|
3
|
Noh E, Begun J, White K, Potthoff S. US hospital engagement in cross-sector partnerships for population health improvement in socioeconomically distressed counties. Public Health 2022; 205:55-57. [DOI: 10.1016/j.puhe.2022.01.020] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2021] [Revised: 12/07/2021] [Accepted: 01/21/2022] [Indexed: 11/29/2022]
|
4
|
Lim MJ, Noh E, Lee RW, Jung KH, Park W. Occurrence of human leukocyte antigen B51-related ankylosing spondylitis in a family: Two case reports. World J Clin Cases 2022; 10:992-999. [PMID: 35127912 PMCID: PMC8790467 DOI: 10.12998/wjcc.v10.i3.992] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/26/2021] [Revised: 10/27/2021] [Accepted: 12/25/2021] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Ankylosing spondylitis (AS) is strongly associated with the human leukocyte antigen (HLA) B27 haplotype. In regions where conventional polymerase chain reaction for HLA typing is available for antigens such as HLA B27 or HLA B51, it is common to perform the HLA B27 test for evaluation of AS. While HLA B27-associated clustered occurrences of AS have been reported in families, we report the first case series of HLA B51-related occurrences of AS in a family.
CASE SUMMARY A father and his daughters were diagnosed with AS and did not have the HLA B27 haplotype. Although they were positive for HLA B51, they exhibited no signs of Behçet’s disease (BD). Of the five daughters, one had AS, and three, including the daughter with AS, were positive for HLA B51. The two daughters with the HLA B51 haplotype (excluding the daughter with AS) exhibited bilateral grade 1 sacroiliitis, whereas the daughters without the HLA B51 haplotype did not have sacroiliitis. Thus, this Korean family exhibited a strong association with the HLA B51 haplotype and clinical sacroiliitis, irrespective of the symptoms of BD.
CONCLUSION It is advisable to check for HLA B51 positivity in patients with AS/spondyloarthropathy who test negative for HLA B27.
Collapse
Affiliation(s)
- Mie Jin Lim
- Rheumatology/Internal Medicine, Inha University, Incheon 22332, South Korea
| | - Eul Noh
- Rheumatology/Internal Medicine, Inha University, Incheon 22332, South Korea
| | - Ro-Woon Lee
- Radiology, Inha University, Incheon 22332, South Korea
| | - Kyong-Hee Jung
- Rheumatology/Internal Medicine, Inha University, Incheon 22332, South Korea
| | - Won Park
- Rheumatology/Internal Medicine, Inha University, Incheon 22332, South Korea
| |
Collapse
|
5
|
Noh E, Moon JM, Chun BJ, Cho YS, Ryu S, Kim D. The clinical role of serum albumin in Organophospate poisoning. Basic Clin Pharmacol Toxicol 2020; 128:605-614. [DOI: 10.1111/bcpt.13546] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2020] [Revised: 12/01/2020] [Accepted: 12/02/2020] [Indexed: 02/06/2023]
Affiliation(s)
- Eul Noh
- Emergency Department Chonnam National University Hospital Gwangju South Korea
| | - Jeong Mi Moon
- Emergency Department Chonnam National University Hwasun Hospital Hwasun‐gun South Korea
- Emergency Department Chonnam National University Medical School Gwangju South Korea
| | - Byeong Jo Chun
- Emergency Department Chonnam National University Hospital Gwangju South Korea
- Emergency Department Chonnam National University Medical School Gwangju South Korea
| | - Yong Soo Cho
- Emergency Department Chonnam National University Hospital Gwangju South Korea
| | - SeokJin Ryu
- Emergency Department Chonnam National University Hospital Gwangju South Korea
| | - Dongki Kim
- Emergency Department Chonnam National University Hospital Gwangju South Korea
| |
Collapse
|
6
|
Chung JE, Noh E, Gwak HS. Evaluation of the predictors of readmission in Korean patients with heart failure. J Clin Pharm Ther 2016; 42:51-57. [PMID: 27791272 DOI: 10.1111/jcpt.12471] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2016] [Accepted: 09/21/2016] [Indexed: 12/27/2022]
Abstract
WHAT IS KNOWN AND OBJECTIVE Various factors contribute to the high rate of readmission among patients hospitalized with heart failure (HF). Determination of these factors is fundamental to identify potential targets for intervention in hospitalized patients. METHODS The retrospective cohort study used a large national insurance database to identify episodes of HF. Clinical information up to 12 months from the index hospitalization was obtained. Depending on their outcome, eligible patients were classified into a 30-day readmission group after discharge or a non-readmission group. Potential predictors of 30-day readmission were categorized by patient, drug therapy and health system utilization factors. RESULTS AND DISCUSSION Heart failure was identified in 19 128 inpatients. Of these, 27·6% were readmitted within 30 days after discharge. The mean Charlson comorbidity index (CCI) score was 5·2 ± 2·9 for the readmission group and 4·3 ± 2·5 for the non-readmission group. The strongest predictors included paralysis [adjusted odds ratio (AOR) 2·27, 95% confidence interval (CI) 1·97-2·62], followed by metastatic cancer (AOR 2·22, 95% CI 1·81-2·72) and loop diuretic therapy (AOR 1·52, 95% CI 1·29-1·79). A prescription of ACE inhibitor or angiotensin receptor blocker at discharge was associated with a 17% decreased risk (AOR 0·83, 95% CI 0·77-0·89). WHAT IS NEW AND CONCLUSIONS Hospitalized patients with HF have a 30-day all-cause readmission rate exceeding a quarter. Post-discharge care should focus on patients with advanced age, acuity of admission, enrolled medical aid, hospitalization exceeding 14 days, higher CCI score, more than 10 prescription drugs at discharge, presence of several comorbidities and loop diuretic therapy, which are independent predictors for 30-day readmission.
Collapse
Affiliation(s)
- J E Chung
- Division of Life and Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, Seoul, Korea
| | - E Noh
- Research Institute of Pharmaceutical Sciences, College of Pharmacy, Sungkyunkwan University, Suwon, Korea
| | - H S Gwak
- Division of Life and Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, Seoul, Korea
| |
Collapse
|
7
|
Dielschneider RF, Xiao W, Yoon JY, Noh E, Banerji V, Li H, Marshall AJ, Johnston JB, Gibson SB. Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling. Cell Death Dis 2014; 5:e1439. [PMID: 25275600 PMCID: PMC4649506 DOI: 10.1038/cddis.2014.391] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2014] [Revised: 07/04/2014] [Accepted: 08/06/2014] [Indexed: 01/03/2023]
Abstract
Chronic lymphocytic leukemia (CLL) can be divided into groups based on biomarkers of poor prognosis. The expression of the tyrosine kinase ZAP-70 (member of the Syk tyrosine kinase family) in CLL cells is associated with shorter overall survival in CLL patients. Currently, there is a lack of targeted therapies for patients with ZAP-70 expression in CLL cells. The tyrosine kinase inhibitor gefitinib has been shown to be effective at induce apoptosis in acute myeloid leukemia through inhibition of Syk. In this study, we sought to test the efficacy of gefitinib in primary human ZAP-70+ CLL cells. We demonstrate that gefitinib preferentially induces cell death in ZAP-70-expressing CLL cells with a median IC50 of 4.5 μM. In addition, gefitinib decreases the viability of ZAP-70+ Jurkat T leukemia cells but fails to affect T cells from CLL patients. Western blot analysis shows gefitinib reduces both basal and B-cell receptor (BCR)-stimulated phosphorylation of Syk/ZAP-70, ERK, and Akt in ZAP-70+ CLL cells. Moreover, gefitinib inhibits the pro-survival response from BCR stimulation and decreases pro-survival proteins such as Mcl-1. Finally, ZAP-70 expression sensitizes Raji cells to gefitinib treatment. These results demonstrate that gefitinib specifically targets ZAP-70+ CLL cells and inhibits the BCR cell survival pathway leading to apoptosis. This represents the likelihood of tyrosine kinase inhibitors being effective targeted treatments for ZAP-70+ CLL cells.
Collapse
Affiliation(s)
- R F Dielschneider
- 1] Department of Immunology, University of Manitoba, Winnipeg, MB, Canada [2] Manitoba Institute of Cell Biology, Winnipeg, MB, Canada
| | - W Xiao
- Manitoba Institute of Cell Biology, Winnipeg, MB, Canada
| | - J-Y Yoon
- 1] Manitoba Institute of Cell Biology, Winnipeg, MB, Canada [2] Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada
| | - E Noh
- Manitoba Institute of Cell Biology, Winnipeg, MB, Canada
| | - V Banerji
- 1] Manitoba Institute of Cell Biology, Winnipeg, MB, Canada [2] Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada [3] Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, MB, Canada
| | - H Li
- Department of Immunology, University of Manitoba, Winnipeg, MB, Canada
| | - A J Marshall
- Department of Immunology, University of Manitoba, Winnipeg, MB, Canada
| | - J B Johnston
- 1] Manitoba Institute of Cell Biology, Winnipeg, MB, Canada [2] Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada
| | - S B Gibson
- 1] Department of Immunology, University of Manitoba, Winnipeg, MB, Canada [2] Manitoba Institute of Cell Biology, Winnipeg, MB, Canada [3] Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada [4] Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, MB, Canada
| |
Collapse
|